{
    "clinical_study": {
        "@rank": "161406", 
        "acronym": "MTX-IR", 
        "arm_group": {
            "arm_group_label": "Abatacept (Autoinjector and Prefilled Syringe)", 
            "arm_group_type": "Experimental", 
            "description": "Abatacept (prefilled syringe) 125 mg/device solution subcutaneously weekly for 3 months\nAbatacept (autoinjector) 125 mg/device solution subcutaneously weekly for 1 month"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to implement a substudy in approximately 120 rheumatoid\n      arthritis (RA) subjects to compare the steady-state serum trough concentration (Cminss),\n      Cmax and AUC(TAU) of subcutaneous (SC) Abatacept injection of 125 mg via the autoinjector\n      and via the BD Hypak\u2122 Physiolis prefilled syringe."
        }, 
        "brief_title": "Methotrexate-Inadequate Response Autoinjector Device Sub Study", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "detailed_description": {
            "textblock": "Study Classification:\n\n        -  Safety: show if the drug is safe under conditions of proposed use\n\n        -  Efficacy: measure of an intervention's influence on a disease or health condition\n\n        -  Safety/Efficacy\n\n        -  Pharmacokinetics: the action of a drug in the body over a period of time including the\n           process of absorption, distribution and localization in tissue, biotransformation, and\n           excretion of the compound."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects who have been treated in the long term (LT) with open-label SC Abatacept for\n             at least 3 months\n\n          -  Must continue to meet inclusion criteria specified in main IM101-174 Study Protocol\n\n        Exclusion Criteria:\n\n          -  Participation in previous device substudy (implemented by Amendment 10)\n\n          -  Must continue to meet exclusion criteria specified in main IM101-174 Study Protocol"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01844895", 
            "org_study_id": "IM101-174 Substudy-2", 
            "secondary_id": "2007-005434-37"
        }, 
        "intervention": {
            "arm_group_label": "Abatacept (Autoinjector and Prefilled Syringe)", 
            "intervention_name": "Abatacept", 
            "intervention_type": "Drug", 
            "other_name": [
                "Orencia", 
                "BMS-188667"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Methotrexate", 
                "Abatacept"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "July 25, 2013", 
        "number_of_arms": "1", 
        "official_title": "Substudy-A Phase IIIB Multicenter, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Abatacept Administered Subcutaneously and Intravenously in Subjects With Rheumatoid Arthritis, Receiving Background Methotrexate, and Experiencing an Inadequate Response to Methotrexate", 
        "overall_official": {
            "affiliation": "Bristol-Myers Squibb", 
            "last_name": "Bristol-Myers Squibb", 
            "role": "Study Director"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Cminss (\u03bcg/mL) trough serum concentration of Abatacept at steady-state on substudy Day 29 (BD Hypak\u2122 Physiolis prefilled syringe)", 
                "safety_issue": "No", 
                "time_frame": "Day 29 (BD Hypak\u2122 Physiolis prefilled syringe)"
            }, 
            {
                "measure": "Cminss (\u03bcg/mL) trough serum concentration of Abatacept at steady-state on substudy Day 113 (autoinjector)", 
                "safety_issue": "No", 
                "time_frame": "Day 113 (autoinjector)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01844895"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Maximum observed serum concentration [Cmax (\u03bcg/mL)] of Abatacept during the sampling period between substudy Days 22 and 29 for the BD Hypak\u2122 Physiolis prefilled syringe", 
                "safety_issue": "No", 
                "time_frame": "Days 22, 24, 25, 26 and 29 (BD Hypak\u2122 Physiolis prefilled syringe)"
            }, 
            {
                "measure": "Maximum observed serum concentration [Cmax (\u03bcg/mL)] of Abatacept during the sampling period between substudy Days 106 and Day 113 for the autoinjector", 
                "safety_issue": "No", 
                "time_frame": "Days 106, 108, 109, 110 and 113 (autoinjector)"
            }, 
            {
                "measure": "Time to achieve Cmax [Tmax (days)] during the sampling period between substudy Days 22 and 29 for the BD Hypak\u2122 Physiolis prefilled syringe", 
                "safety_issue": "No", 
                "time_frame": "Days 22, 24, 25, 26 and 29 (BD Hypak\u2122 Physiolis prefilled syringe)"
            }, 
            {
                "measure": "Time to achieve Cmax [Tmax (days)] during the sampling period between substudy Days 106 and 113 for the autoinjector", 
                "safety_issue": "No", 
                "time_frame": "Days 106, 108, 109, 110 and 113 (autoinjector)"
            }, 
            {
                "measure": "Area under serum concentration-time [AUC(TAU)] profile over dosing interval during sampling period between substudy Days 22 and 29 for BD Hypak\u2122 Physiolis prefilled syringe", 
                "safety_issue": "No", 
                "time_frame": "Days 22, 24, 25, 26 and 29 (BD Hypak\u2122 Physiolis prefilled syringe)"
            }, 
            {
                "measure": "Area under serum concentration-time [AUC(TAU)] profile over dosing interval during sampling period between substudy Days 106 and 113 for autoinjector", 
                "safety_issue": "No", 
                "time_frame": "Days 106, 108, 109, 110 and 113 (autoinjector)"
            }, 
            {
                "description": "Frequency distribution of all AEs will be generated", 
                "measure": "Safety and tolerability evaluation are based on clinical adverse events (AEs)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Day 113"
            }, 
            {
                "description": "Incidence of a positive response during the substudy will be summarized as well as by injection device", 
                "measure": "Immunogenicity assessment based on analysis of anti-Abatacept antibodies in serum", 
                "safety_issue": "Yes", 
                "time_frame": "Days 29 and 113"
            }, 
            {
                "measure": "Abatacept systemic exposure over time and during the switch from BD Hypak\u2122 Physiolis prefilled syringe to the autoinjector using trough serum concentration (Cmin)", 
                "safety_issue": "No", 
                "time_frame": "Days 1, 22, 29, 57, 85, 106, and 113"
            }
        ], 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}